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ARTICLE
Correcting glucose-6-phosphate dehydrogenase
deﬁciency with a small-molecule activator
Sunhee Hwang 1, Karen Mruk 1,2,6, Simin Rahighi3,7, Andrew G. Raub1,4, Che-Hong Chen1, Lisa E. Dorn 1,8,
Naoki Horikoshi3, Soichi Wakatsuki3,5, James K. Chen 1,2 & Daria Mochly-Rosen 1
Glucose-6-phosphate dehydrogenase (G6PD) deﬁciency, one of the most common human
genetic enzymopathies, is caused by over 160 different point mutations and contributes to
the severity of many acute and chronic diseases associated with oxidative stress, including
hemolytic anemia and bilirubin-induced neurological damage particularly in newborns. As no
medications are available to treat G6PD deﬁciency, here we seek to identify a small molecule
that corrects it. Crystallographic study and mutagenesis analysis identify the structural and
functional defect of one common mutant (Canton, R459L). Using high-throughput screening,
we subsequently identify AG1, a small molecule that increases the activity of the wild-type,
the Canton mutant and several other common G6PD mutants. AG1 reduces oxidative stress
in cells and zebraﬁsh. Furthermore, AG1 decreases chloroquine- or diamide-induced oxidative
stress in human erythrocytes. Our study suggests that a pharmacological agent, of which AG1
may be a lead, will likely alleviate the challenges associated with G6PD deﬁciency.
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Reduced glutathione (GSH) provides the cellular ﬁrst line ofdefense against oxidative stress-induced injury, which canbe maintained by NADPH generated mainly via the pen-
tose phosphate pathway and its rate-limiting enzyme, glucose-6-
phosphate dehydrogenase (G6PD; Fig. 1a). Accordingly, missense
DNA mutations that impair G6PD activity or stability result in
increased oxidative stress and a spectrum of disease phenotypes
featuring, most commonly, hemolytic anemia, and collectively
called G6PD deﬁciency1. In particular, G6PD is essential in
preserving the integrity of erythrocytes because, lacking mito-
chondria, they have no other NADPH-generating enzymes to
protect against oxidative stress2.
G6PD deﬁciency represents one of the most common inherited
and sex-linked enzymopathies. The G6PD gene maps to the X-
chromosome; thus, the phenotype is manifest fully in males
whereas female heterozygotes display varying degrees of G6PD
deﬁciency, due to alternate X-chromosome inactivation3,4. G6PD
deﬁciency afﬂicts more than an estimated 400 million individuals
worldwide, many of whom live in malaria endemic regions.
Impaired anti-oxidant defense in G6PD-deﬁcient erythrocytes
makes them vulnerable to early membrane damage and ulti-
mately phagocytosis when infected with malaria5. This mechan-
ism that results in limiting the propagation of the parasite in the
bloodstream explains how G6PD deﬁciency provides resistance
against malaria4–6.
Symptoms of G6PD deﬁciency are triggered by exposure to
certain foods, medications, infection and/or environmental fac-
tors2,4. For example, consumption of fava beans causes oxidative
stress to erythrocytes possibly by two main toxins, vicine or
convicine, thus triggering acute hemolytic episode (favism) in
affected subjects7. G6PD-deﬁcient individuals are also at a high
risk of severe hemolysis when given anti-malarial drugs, such as
quinine, primaquine or chloroquine, through irreversible oxida-
tive activity of their metabolites on erythrocytes8,9. G6PD deﬁ-
ciency can be life-threatening, especially in newborns, leading to
bilirubin-induced neurological injury and bilirubin encephalo-
pathy (kernicterus) and even to death10–15. In a recent study, a
systematic analysis of 2253 articles discussing G6PD revealed that
dysregulation of G6PD is also associated with autoimmune dis-
eases and metabolic disorders, indicating that clinical risks
associated with G6PD deﬁciency are likely underestimated16. As
there are currently no means to correct G6PD deﬁciency, there is
no treatment for the disease; management mainly consists of
supportive care and discontinuation of triggers. The use of anti-
oxidants such as vitamin E or selenium has proven to be inef-
fective in treating G6PD deﬁciency17–19.
On the other hand, based on studies performed in Sardinia,
G6PD deﬁciency has some beneﬁcial effect on longevity20. In
studies using dehydroepiandrosterone (DHEA), an inhibitor of
G6PD (that is also an adrenal steroid), loss of G6PD function has
been suggested to prevent cancer progression20,21. Despite all the
beneﬁcial effects, the detrimental effect of G6PD deﬁciency are
still clear in hemolytic anemia and kernicterus of infancy. Given
the risk of hemolytic crisis and related sequelae from various
triggers in affected subjects in both malaria endemic and non-
endemic regions, we believe that developing a pharmacological
agent that corrects G6PD deﬁciency may beneﬁt affected
individuals.
G6PD is functionally active as a dimer or a tetramer22. Each
monomer has a catalytic nicotinamide adenine dinucleotide
phosphate (NADP+)-binding domain and β+α domain, con-
taining an additional binding site for NADP+ that structurally
stabilizes the enzyme (Fig. 1b)23,24. The glucose 6-phosphate
(G6P)-binding site is located between these two domains
(Fig. 1b). Using different informatics tools, we recently demon-
strated that the majority of the variants that cause severe (<10%
of normal G6PD activity, class I and class II) or mild (10–60% of
normal G6PD activity, class III) deﬁciency are primarily located
in those functional regions of the enzyme, disturbing the
enzyme’s activity and stability25.
Here we present a comprehensive report describing the
molecular basis for G6PD deﬁciency with Canton variant (R459L)
and our efforts to restore its decreased function using a small
molecule, AG1. Our study provides the ﬁrst step in identifying a
potential therapeutic approach to correct G6PD deﬁciency.
Results
Canton G6PD variant has reduced activity and stability. We
ﬁrst began our efforts focusing on the Canton variant, with the
mutation R459L, located in the β+α domain (Fig. 1b). Canton
G6PD is prevalent in China and Southeast Asia (50–60% of the
variants26,27), causing severe deﬁciency (class II). Recombinant
Canton G6PD enzyme showed only 18% of normal G6PD activity
with lower KM for both NADP+ and G6P (Fig. 1c), which is
consistent with the biochemical characteristics analyzed using
blood samples derived from subjects carrying the Canton var-
iant28. Relative to the wild-type (WT) enzyme, Canton G6PD also
displayed impaired ability to form tetramers in the presence of
increased concentrations of the cofactors that facilitate tetramer
formation, NADP+ or MgCl229,30, when cross-linked by glutar-
aldehyde (Supplementary Fig. 1a). This reduced oligomerization
state of the Canton G6PD may contribute to its reduced enzy-
matic activity. Furthermore, the Canton variant was less ther-
mostable; its T1/2, the temperature at which the enzyme retains
half of its catalytic activity, was 42.6 °C, which is 4.6 °C lower than
T1/2 of WT enzyme (Fig. 1d). Canton G6PD was more susceptible
to degradation by chymotrypsin relative to the WT enzyme,
which corresponded with a signiﬁcantly decreased enzymatic
activity (Fig. 1e). This suggests that Canton G6PD may undergo
higher conformational ﬂuctuation, leading to a greater accessi-
bility to proteases and its reduced thermostability31.
We also show that the Canton variant was less stable than WT
G6PD in lymphocytes derived from a male subject carrier with a
Canton mutation in G6PD; 24 h after cycloheximide treatment
(50 μg mL−1) to inhibit de novo protein biosynthesis, the level of
the Canton variant protein was ~33% lower than the WT enzyme
(Fig. 1f and Supplementary Fig. 1b). G6PD activity in lysates of
lymphocytes of the Canton variant carrier was ~90% lower than
G6PD activity in normal lymphocytes (Fig. 1g), which coincided
with low levels of total GSH and increased levels of reactive
oxygen species (ROS) (Fig. 1h, i). Moreover, the viability of the
lymphocytes of the Canton variant carrier was ~50% lower
relative to normal lymphocytes when cultured under the stress
condition induced by serum starvation (Fig. 1j).
The same results were observed in SH-SY5Y neuronal cells
transiently expressing WT G6PD or the Canton variant (His-
tagged); Canton G6PD protein levels dropped by 50% within 24 h
of cycloheximide treatment, as compared to 20% decrease of WT
G6PD (Supplementary Fig. 1c). SH-SY5Y cells expressing the
Canton variant also showed lower G6PD enzymatic activity in the
lysates, and a lower level of GSH, a higher level of ROS, and lower
cell viability in culture (Supplementary Fig. 1d, e, f, g) and
knockdown of G6PD by siRNA reduced cell viability, recapitulat-
ing the phenotype of G6PD deﬁciency (Supplementary Fig. 1h).
Canton mutation loses essential inter-helical interactions. To
elucidate the molecular basis of the reduced stability and activity
of Canton G6PD, we examined the crystal structures of WT and
Canton G6PD at 1.9 Å and 2.6 Å resolution, respectively
(Table 1). Although no NADP+ was added to protein solution
prior to the crystallization, both crystal structures contained
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NADP+ at the second NADP+-binding site (structural NADP+-
binding site) in the β+α domain (Supplementary Fig. 2a). (The
stability of the enzyme with NADP+ association at this site has
been previously reported and NADP+ can be removed by incu-
bating the enzyme with G6P24,30.) The overall conformations of
WT and Canton G6PD were very similar, as indicated by a root-
mean-square deviation of 0.6 Å for the superimposition of Cα
atoms (Fig. 2a). However, we noticed a loose helical interaction
between the helix (αn), containing the Canton variant-R459L,
and an adjacent helix (αe) (Fig. 2b, left panel), which was not
described in previously reported structures24. In WT G6PD, R459
forms electrostatic and hydrogen bond interactions with D181
and N185 on the adjacent helix (αe), whereas Canton mutation
does not, resulting in loosened inter-helical interactions and
displacements of the helix (αe) and a proceeding loop consisting
of K171, P172, F173, G174, and R175, several amino acids away
from R459-interacting residues on the helix (αe) (Fig. 2b, right
panel). In particular, K171 and P172 are the key residues involved
in positioning of G6P and NADP+ in their binding pockets23,24.
Thus, the loose inter-helical interaction in the Canton variant is
likely to be a major driving force for positioning the loop and thus
changing the orientations of these residues. In 7 out of 8 mole-
cules in the asymmetric unit of the Canton variant structure,
P172 was observed in the trans conformation, consistent with
previous data23,24 and accordingly, the side chain of K171 was
oriented away from catalytic NADP+ and G6P binding pockets
(Fig. 2b, right panel, and Supplementary Fig. 2b, c). K171A and
P172G mutations in WT G6PD completely abolished the
enzyme’s catalytic activity, indicating the importance of these
residues in catalysis (Supplementary Fig. 2d).
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Fig. 1 Canton G6PD (R459L) variant is biochemically different from WT G6PD. a Enzymatic scheme of G6PD activity. b A linear map of G6PD domain
structure with most common variants indicated. c Catalytic activity of recombinant WT G6PD and Canton G6PD enzymes with kinetic parameters (n= 5,
****p < 0.0001). d Thermostability of WT G6PD and Canton G6PD enzyme (n= 3, **p= 0.003). e G6PD protein levels and residual G6PD activity
(normalized to NT (no treatment) of each enzyme) after incubation with chymotrypsin for 1 h (n= 3 for protein level assay, **p= 0.0046; n= 2 for enzyme
assay, *p= 0.024). f Protein stability assessment with cycloheximide treatment (50 μg mL−1), blocking de novo protein biosynthesis, in lymphocytes
derived from corresponding subjects (n= 3, *p= 0.013). Protein levels were normalized to the level of each enzyme at 0 h (no treatment). g G6PD activity
was lower in cell lysates with Canton variant (n= 4, ****p < 0.0001). h, i, j Lymphocytes with Canton variant generated less GSH and more reactive oxygen
species (ROS) and were less viable (n= 4, (n= 3 for Fig. 1i), *p < 0.05, **p < 0.01). Error bars represent mean ± SEM. Statistical differences were calculated
by two-tailed unpaired Student’s t-test. NT: no treatment, WT: wild-type, Chy: chymotrypsin
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We further mutated the R459-interacting residues, D181 and
N185, to alanine in WT G6PD to determine the importance of
the inter-helical interactions and found that these point-mutated
enzymes are biochemically similar to the Canton variant; they
exhibited about 20% of the normal activity, with lower KM values
for both NADP+ and G6P and lower T1/2 values (Fig. 2c and
Supplementary Fig. 2e). These mutants were also more
susceptible to proteolytic digestion, relative to WT G6PD
(compare Fig. 2d to Fig. 1e). Taken together, these data support
the importance of the inter-helical interaction between R459 and
D181 and N185 for catalytic activity and stability of the enzyme
and provides a structural insight into the biochemical defects of
the Canton variant. Indeed, other human mutations located
around this helical interaction site, such as P172S (<10% enzyme
activity), F173L (<10% enzyme activity), and D181V (10–60%
enzyme activity), cause moderate to severe G6PD deﬁciency32–34,
likely because they are predicted to undergo similar conforma-
tional changes based on our observation.
AG1 activates and stabilizes G6PD mutants. Our biochemical
and structural studies led us to determine whether improving the
activity of G6PD variants with a pharmacological agent can
provide a new therapeutic approach to reduce the risk of
pathologies implicated in patients with G6PD deﬁciency. To this
end, we screened for agonists of G6PD (AGs) using the recom-
binant Canton G6PD enzyme by a high-throughput screen (HTS)
and identiﬁed one agonist, 2,2’-disulfanediylbis(N-(2-(1H-indol-
3-yl)ethyl)ethan-1-amine) (AG1, Mr= 438.1912) (Supplementary
Fig. 3a). We conﬁrmed that the active species in the HTS sample
is a product resulting from thiol oxidation under ambient con-
ditions35, which was validated by mass spectrometry and nuclear
magnetic resonance spectroscopy (Supplementary Fig. 3a and
Supplementary Note 1). AG1 increases the activity of Canton
G6PD up to 1.7-fold with EC50≈3 μM and WT G6PD by about
20% over basal activity (Fig. 3a, b and Supplementary Fig. 3b).
Although AG1 was a mild activator, it changed the kinetic
parameters of Canton G6PD, indicating that AG1 may facilitate
improved binding of NADP+ and/or G6P to the enzyme (Fig. 3c).
We found that AG1 also promoted formation of dimers, as
determined by partial native gel electrophoresis (Fig. 3d). The
small increase observed in molecular weight of the monomeric
G6PD might be due to either some modiﬁcation of the enzyme by
AG1 or an equilibrium shift toward dimeric states. When the
recombinant Canton G6PD enzyme was incubated with G6P to
remove the structural NADP+, the dimeric G6PD was destabi-
lized, dissociating into a monomer (Fig. 3e). In the presence of
AG1, however, the equilibrium shifted toward a dimer (Fig. 3e),
further indicating that AG1 stabilizes a dimeric form of the
enzyme. AG1 had no effect on the dimerization or activity of
several other NAD- or NADP+-dependent dimeric or tetrameric
enzymes, including 6-phosphogluconate dehydrogenase (6PGD),
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), aldehyde
dehydrogenase 2 (ALDH2), and aldehyde dehydrogenase 3A1
(ALDH3A1) (Supplementary Fig. 3c). Whereas 1 μM of AG1
increased the viability of SH-SY5Y cells by 20%, it had no effect
when G6PD was knocked down by siRNA, supporting the spe-
ciﬁcity of AG1 toward G6PD (Supplementary Fig. 3d). Note also
that the decrease in viability by the knockdown of G6PD implies
the critical role of G6PD for cell survival. AG1 also reduced the
susceptibility of Canton G6PD to proteolysis (Fig. 3f) and mildly
improved its stability in lymphocytes (Fig. 3g and Supplementary
Fig. 3e). The enzymatic activity in lymphocyte lysates with the
Canton variant (~10% of normal activity) was enhanced by 78%
in the presence of AG1 (Fig. 3h). The levels of GSH were slightly
higher after treatment with AG1 for 24 h, which coincided with
decreased ROS levels and improved cell viability (Fig. 3i–k) in the
lymphocytes cultured under the serum starvation stress. AG1
treatment also increased the proteolytic stability of Canton G6PD
in SH-SY5Y cells (Supplementary Fig. 3f). There was also a mild
increase in G6PD activity, GSH levels, and viability of these cells
together with a decrease in ROS levels (Supplementary Fig. 3g, h,
i, j). Finally, as predicted, the activity of Canton variant-
mimicking mutations that we generated (Fig. 2c, d), D181A
and N185A, were similarly affected by AG1, as measured by
increased activity and proteolytic stability (Supplementary Fig. 4a,
b, c), suggesting that AG1 may correct a structural defect com-
mon to mutations that disturb that helical structure (Fig. 2b).
Because G6PD exhibits cooperative folding36 and AG1 increased
and/or stabilized G6PD dimer levels, we next examined the
possibility that binding of AG1 to the enzyme could correct other
point mutation-containing G6PD variants outside the αe-αn inter-
helical interaction sites. We focused on A− (V68M & N126D),
Mediterranean (S188F), and Kaiping (R463H) G6PD (Fig. 1b), the
three most common human variants in non-overlapping regions of
the world causing mild to severe deﬁciency (Africa, Mediterranean
and Southeast Asia, respectively). AG1 activated all these variants by
up to 2-fold and increased the levels of the dimeric state (Fig. 3l, m).
AG1 also stabilized G6PD in ﬁbroblasts derived from a subject who
carries Mediterranean mutation following cycloheximide treatment
(Fig. 3n and Supplementary Fig. 5a). The lysate of human ﬁbroblasts
with the Mediterranean variant had only 22% activity of control
human ﬁbroblasts, but AG1 increased that activity by 50%
(Supplementary Fig. 5b). Fibroblasts carrying the Mediterranean
variant generated more ROS and less GSH under stress induced by
serum starvation relative to ﬁbroblasts from control subject, which
was signiﬁcantly blunted by AG1 treatment (Fig. 3o, p). Lower cell
viability under the same condition was also improved by 22% in the
presence of AG1 (Supplementary Fig. 5c). When Mediterranean
G6PD expression was knocked down by siRNA, the viability was
Table 1 Diffraction data and reﬁnement statistics
G6PD WT G6PD Canton (R459L)
Data collection
Beamline SSRL BL12-2 ALS BL 5.0.2
Space group F222 P212121
Cell dimensions
a, b, c (Å) 60.6, 173.4, 215.9 127.1, 206.2, 211.8
α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Wavelength (Å) 1.0 1.0
Resolution (Å) 50.0–1.9 (1.95–1.90) 50.0–2.6 (2.74–2.60)
CC (½) 1.00 (0.82) 1.00 (0.52)
Rmerge 0.12 (0.79) 0.15 (1.44)
I/σI 11.0 (3.0) 10.5 (1.6)
Completeness (%) 95.3 (91.3) 100.0 (100.0)
Redundancy 5.7 (5.7) 7.3 (7.5)
Reﬁnement
Resolution (Å) 50.0–1.9 50.0–2.6
No. reﬂections 37,018 171,050
Rwork/Rfree 17.2/21.2 18.7/21.1
No. atoms
Protein 3946 31,554
Water 406 537
Other 78 598
B-factors
(average)
Protein 24.6 36.3
Water 34.9 45.7
Other 38.8 57.7
R.m.s. deviation
Bond lengths (Å) 0.015 0.014
Bond angles (°) 1.786 1.734
PDB ID 6E08 6E07
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further dropped by 23%, and AG1 did not rescue it (Supplementary
Fig. 5c), indicating the selective effect of AG1 for G6PD. Taken
together, these data raise the possibility that by increasing (or
stabilizing) the levels of dimeric G6PD and/or increasing the enzyme
activity, AG1 may represent a lead compound for a drug to treat not
only Canton-like mutations, but also some of the other most
common G6PD deﬁciencies in humans.
AG1 reduces oxidative stress in zebraﬁsh. Capitalizing on a
recent report describing a morpholino-generated G6PD-deﬁcient
zebraﬁsh model, in which exposure to pro-oxidants resulted in
cardiac edema and a brisk hemolysis37, we next set out to deter-
mine the effect of AG1 in vivo. Using zebraﬁsh embryos, we ﬁrst
conﬁrmed that embryos develop normally at concentrations <10
μM of AG1 (Fig. 4a and Supplementary Fig. 6a), indicating that
AG1 is not toxic to developing zebraﬁsh embryos. We next used
the anti-malarial drug, chloroquine, a common trigger for hemo-
lytic crisis in G6PD-deﬁcient humans4,37, to induce an oxidative
challenge in the zebraﬁsh embryos and found that chloroquine
(100 μgmL−1) treatment at 24 h post fertilization (hpf) led to
pericardial edema and increased ROS levels (Fig. 4a, b), which was
consistent with the primaquine-induced phenotypes observed in a
morpholino-based G6PD-deﬁcient zebraﬁsh model37. Upon
chloroquine treatment, hemoglobin staining was also slightly
reduced (Supplementary Fig. 6b). Under the same condition,
AG1 signiﬁcantly reduced ROS levels, resulting in less embryos
exhibiting pericardial edema (Fig. 4a, b and Supplementary Fig. 6a;
scores were determined by an observer blinded to the treatment
group) and mildly increased hemoglobin staining (Supplementary
Fig. 6b). Although a slight increase in G6PD activity was observed
in lysates of pooled AG1-treated embryos, there was a signiﬁcant
increase in total NADPH levels possibly due to the increase in the
product of G6PD downstream, 6-phosphogluconate, which serves
as a substrate for the downstream enzyme, 6-phosphogluconate
dehydrogenase (6PGD), another NADPH-producing enzyme in
the pathway (Fig. 4c). As expected, the attenuation of pericardial
edema was speciﬁc to G6PD deﬁciency, as pericardial edema due to
mesoderm defects in tbx16 mutants was not corrected by AG1
treatment (Supplementary Fig. 6c, d)38,39. To further conﬁrm the
speciﬁcity of AG1 in vivo, we used CRISPR-Cas9 to generate loss-
of-function F0 embryos (crispants). g6pd crispants had a lower
G6PD level (Supplementary Fig. 6e), a 51% higher level of ROS, a
67% lower level of G6PD activity and a 58% lower NADPH level,
and increased pericardial edema (Fig. 4d–f; scores were determined
by an observer blinded to the treatment group). Treatment with
1 μM AG1 did not signiﬁcantly affect these parameters in the g6pd
crispants (Fig. 4d–f). Note also that there was a slight (albeit not
statistically signiﬁcant) increase in the number of crispant embryos
exhibiting reduced hemoglobin staining (Supplementary Fig. 6f).
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AG1 reduces hemolysis of human erythrocytes. We next
determined whether AG1 protects erythrocytes from oxidative
stress. Our preliminary study using human erythrocytes from
seven healthy subjects showed that AG1 (5 μM) reduces the
extent of hemolysis, when erythrocyte suspension (5%) was
exposed to either 1 mM chloroquine (CQ) or diamide (a GSH
oxidant), suggesting anti-hemolytic potential of AG1 (Fig. 5a). In
support of this, AG1 increased GSH levels and reduced ROS
levels together with increased G6PD activity under these drug-
induced oxidative stress (Fig. 5b–d). Oxidative stress impairs
erythrocyte membrane integrity through initial oxidation of
hemoglobin, leading to the precipitation of Heinz bodies and
band 3 (a major erythrocyte membrane protein) clustering; thus,
band 3 clustering serves as an essential molecular marker of
erythrocyte removal40. Using erythrocytes isolated from 9 to 11
individual whole blood samples, we conﬁrmed that band 3 pro-
tein is aggregated with either chloroquine (CQ) or diamide
treatment, which was alleviated by AG1 treatment (Fig. 5e and
Supplementary Fig. 7a). This suggests that AG1 contributes to
stabilizing erythrocyte membranes. Red blood cell transfusion is
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commonly used clinical therapy, but structural and functional
changes in erythrocytes during storage, collectively referred to as
storage lesion, remain concerned in transfusion practice41. Sto-
rage under conventional conditions is considered as oxidative
stress for erythrocytes, as evidenced by increase in ROS over time
and accumulation of oxidative biomarkers42,43. Thus, we deter-
mined that whether AG1 can improve preservation during
refrigerated storage by monitoring the degree of hemolysis over
28 days. We found that AG1 (1 μM) reduces hemolysis over time
by an average of 12% at day 28 (Fig. 5f and Supplementary
Fig. 7b). Accordingly, the protein leakage from the treated ery-
throcytes was decreased as well (Fig. 5g and Supplementary
Fig. 7c), which corresponded with increased G6PD activity
(Fig. 5h). These data suggest that AG1-like compounds can serve
as a novel preservative for prolonged storage of erythrocytes and
impact to a broader population as well as G6PD-deﬁcient
patients.
Discussion
In humans, in addition to the role of G6PD in preventing
hemolysis (erythrocyte lysis), the anti-oxidant property of G6PD
may relate to development of a variety of other pathologies,
including kidney injury, heart failure, psychiatric disorder, dia-
betes, cholelithiasis, and cataract44–52, suggesting that G6PD
deﬁciency can be an underestimated risk factor for multiple
human pathologies. Because AG1 increased the impaired activity
of several common G6PD variants, our study suggests that a
single pharmacological agent may provide treatment for several
major G6PD enzymopathies, affecting many millions of people
worldwide. Such a drug may also help prevent or reduce the
sequelae of G6PD deﬁciency and/or synergize with other pallia-
tive treatments such as illumination for kernicterus53,54. We
expect many other pathologies associated with G6PD deﬁciency,
as aforementioned, to be affected by such treatment as well.
Treatment with AGs may also be beneﬁcial to G6PD-deﬁcienct
populations in developing countries, in which the use of hemo-
lytic crisis-triggering drugs, like anti-malarial drugs (primaquine
and chloroquine), are still common. We believe that AG1-like
drugs may also be useful for preservation of blood for transfusion,
as evidenced in Fig. 5 and for subjects with WT G6PD with other
diseases associated with increased oxidative stress.
Human studies demonstrate that clinical pathology related to
G6PD deﬁciency, at least as reﬂected by hemolytic crisis, occurs
in subjects who carry a variant with <60% activity relative to the
subjects with WT G6PD55. Therefore, although AG1 is safe, an
optimal AG should be improved, to increase the catalytic activity
in G6PD-deﬁcient subjects to at least 60% of normal. None-
theless, based on our initial studies, AG1 should be viewed as a
lead compound to correct G6PD deﬁciency and also to treat
subjects with WT G6PD at risk of oxidative stress. Our current
effort focuses on improving the biochemical and pharmacological
features of AG1 through further medicinal chemistry efforts and
structural studies. Finally, identifying small-molecule enzyme
activators is still considered a challenging task in the ﬁeld of drug
discovery and development56, and even less common is the ability
to identify a small molecule that corrects functional defect due to
different mutations; AG1 represents a compound that does both.
Methods
Materials. Antibodies used in this study were principally purchased from Santa
Cruz Biotechnology (G6PD (G-12): SC-373886 (dilution 1:1000), 6PGD (G-2): SC-
398977 (dilution 1:1000), His (HIS.H8): SC-57598 (dilution 1:1000), Enolase (H-
300): SC-15343 (dilution 1:1000)), Cell Signaling Technology (beta actin
(8H10D10): 3700 S (dilution 1:1000)), Everest Biotech (G6PD: EB07841 (dilution
1:1000)), Advance Immunochemical (GAPDH (6C5): 6C5 (dilution 1:2000)), and
Abcam (G6PD: AB87230 (dilution 1:1000), band 3 (EPR1426): AB108414 (dilution
1:1000)). TALON Superﬂow (28-9575-02) and bovine thrombin (91-030) were
purchased from GE Healthcare and BioPharma for protein puriﬁcation. Pfu Turbo
polymerase (600252) used for site-directed mutagenesis was purchased from
Agilent Technologies. Chymotrypsin was purchased from Promega (V1061). Cell
counting kit-8 (CK04) and glutathione quantiﬁcation kit (T419) were purchased
from Dojindo. Cycloheximide (C7698) and chloromethyl-2’,7’-dichlorodihydro-
ﬂuorescein diacetate (CM-H2DCFDA, C6827) were purchased from Sigma and
Thermo Fisher Scientiﬁc, respectively. Glutathione assay kit (703002) used for
blood assays was purchased from Cayman Chemical.
Cell culture. Lymphocytes derived from a normal subject (HG 00866) and a
G6PD-deﬁcient subject carrying the Canton variant (HG 02367) were purchased
from Coriell Institute and cultured in RPMI 1640 supplemented with 15% fetal
bovine serum (FBS), 100 UmL−1 penicillin, and 100 μg mL−1 streptomycin. An
SH-SY5Y neuroblastoma cell line (ATCC CRL-2266) was cultured in Dulbecco’s
Modiﬁcation of Eagle’s Medium/Ham’s F-12 50/50 Mix supplemented with 10%
FBS, 100 UmL−1 penicillin, and 100 μg mL−1 streptomycin. A ﬁbroblast cell line
derived from a G6PD-deﬁcient subject carrying the Mediterranean variant and
normal ﬁbroblast cell line as control were purchased from Coriell Institute (GM
01152) and Thermo Fisher Scientiﬁc (C0135C), respectively, and cultured in
minimum essential medium supplemented with 15% FBS, 100 UmL−1 penicillin,
and 100 μg mL−1 streptomycin. All the cell lines were maintained at 37 °C in a
humidiﬁed incubator with an atmosphere of 5% of CO2 and 95% air.
Plasmid construction and site-directed mutagenesis. The gene encoding WT
G6PD was inserted into the pET-28a vector, using NdeI and SalI restriction
enzyme sites. Site-directed mutagenesis was performed to generate G6PD variants
using appropriate primer sets (Supplementary Table 1) according to the manu-
facturer’s guidelines (Agilent-Quikchange site-directed mutagenesis). Brieﬂy, the
PCR reaction of 50 μL contained 10–50 ng of template, 125 ng of primers, 200 μM
dNTPs, and 2.5 units of Pfu Turbo DNA polymerase. The reaction was initiated at
95 °C for 30 s to denature the template DNA, followed by 18 ampliﬁcation cycles
(95 °C for 30 s, 55 °C for 1 min and 68 °C for 7 min). All constructs were veriﬁed by
sequencing.
Protein expression and puriﬁcation. G6PD and its variants were expressed in E.
coli C43 (DE3). When the culture density reached an OD600 of 0.5–0.6, 0.5 mM
Fig. 3 AG1 (activator of G6PD) induces biochemical changes in the Canton variant. a Increased activity of Canton G6PD enzyme by AG1 (n= 5, ***p=
0.0002, two-tailed unpaired Student’s t-test) and b a dose response curve of AG1. c AG1 changed kinetic parameters of Canton G6PD. d AG1 promoted
dimerization of Canton G6PD (n= 3). e Size-exclusion FPLC (calibrated Superdex 75 10/300 GL column) proﬁle of puriﬁed Canton G6PD in the presence
of G6P or AG1. f AG1 reduced proteolytic susceptibility of Canton G6PD (n= 3, ***p < 0.001, *p < 0.05, one-way ANOVA). The protein levels were
normalized to the non-treated (NT) enzyme level. g Cycloheximide-chase assay using lymphocytes carrying the Canton variant (n= 3). Protein levels were
normalized to the level of each enzyme at time 0 h. h, i, j AG1 increased G6PD activity in cell lysates with the Canton variant (n= 4, **p= 0.0032, two-
tailed unpaired Student’s t-test), mildly enhanced a GSH level (n= 7, *p= 0.0282, two-tailed unpaired Student’s t-test) and reduced a ROS level in culture
(n= 6, *p= 0.0452, two-tailed unpaired Student’s t-test). k AG1 increased viability of lymphocytes carrying the Canton variant (n= 6, **p= 0.003, two-
tailed unpaired Student’s t-test). l, m AG1 activated other major G6PD variants, including A− (V68M, N126D; blue spheres), Mediterranean (S188F, orange
spheres), and Kaiping (R463H, yellow spheres) variants, respectively (n= 4, ****p < 0.0001, **p < 0.01, *p= 0.011, one-way ANOVA), and promoted their
dimerization (n= 3). Purple spheres in the structure represent the side chain of R459. n Cycloheximide-chase assay using ﬁbroblasts carrying the
Mediterranean variant (n= 4, *p= 0.0437, two-tailed unpaired Student’s t-test). o, p AG1 signiﬁcantly decreased a ROS level (n= 6, ***p= 0.0001, ****p <
0.0001, one-way ANOVA) and increased a GSH level in those cultures (n= 3, *p= 0.0214, ****p < 0.0001, one-way ANOVA). 100 μM and 1 μM of AG1
were used for in vitro assays and cell-based assays, respectively. 5% DMSO (stock) was used as vehicle. For FPLC assay, 500 μM AG1, 200 μg of Canton
G6PD recombinant enzyme and 10mM G6P were used. Cells were subjected to serum starvation for 48 h. Error bars represent mean ± SEM. MW:
molecular weight, FPLC: fast protein liquid chromatography, NT: no treatment, Veh: vehicle, WT: wild-type, Med: Mediterranean ﬁbroblast
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IPTG was added to induce the protein expression. After culturing at 28 °C over-
night, the bacteria were centrifuged, and the pellets were lysed by sonication in
buffer containing 50 mM Tris (pH 7.4), 300 mM NaCl, 5% glycerol, 0.4 mM PMSF,
1 mgmL−1 lysozyme, 0.1% Triton X-100 and protease inhibitor cocktail (Sigma
P8340). G6PD was then puriﬁed by incubating the supernatant with TALON
Superﬂow resin equilibrated with 1 bed volume of equilibration buffer (50 mM Tris
(pH 7.4), 300 mM NaCl and 5 mM imidazole) at 4 °C for 1 h. The resin was washed
with 5 bed volumes of wash buffer (50 mM Tris (pH 7.4), 300 mM NaCl and 20
mM imidazole) in a gravity-ﬂow column and resuspended in 5 mL of equilibration
buffer for size exclusion chromatography (50 mM Tris (pH 7.4) and 150 mM
a
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Fig. 4 AG1 attenuates ROS-induced pericardial edema in a G6PD-dependent manner. a Embryos were treated at 24 hpf with 1 μM AG1 with and without
chloroquine (CQ; 100 μgmL−1) and scored at 32 hpf. Representative phenotypic images of pericardial edema and pooling (magenta arrows) are provided on the
left (scale bar: 300 μm). Embryo orientation is lateral view, anterior left. Raw counts used for chi-square analysis and calculated p value are included in table
below. b ROS levels in individual WT embryos from three independent clutches. Embryos were treated at 24 hpf for 5 h before ROS measurement. Error bars
represent mean ± SD (***p < 0.001, ns= not statistically signiﬁcant, p > 0.99, Kruskal–Wallis multiple comparison test, adjusted p value using Dunn’s test).
c G6PD activity and NADPH levels were measured using the lysates of pooled embryos (from two independent clutches). Error bars represent mean ± SEM
(***p=0.0003, two-tailed unpaired Student’s t-test). d Embryos were injected with either sgRNA targeting exon 10 of g6pd (Guide alone) or sgRNA+Cas9
protein (Guide+Cas9, G6PD KO (knockout)) to generate G6PD F0 crispants. Representative phenotypic images of pericardial edema and pooling (magenta
arrows) are provided on the left (scale bar: 300 μm). Treatment conditions are the same as in a. Raw counts used for chi-square analysis and calculated p value
are included in table below. e ROS levels in individual embryos with sgRNA or sgRNA+Cas9 (G6PD KO) protein injection. Treatment conditions and the
statistics are the same as in b (*p=0.0267, **p < 0.01, ****p < 0.0001, ns= not statistically signiﬁcant). f G6PD activity and NADPH levels were measured with
lysates of pooled embryos from three independent experiments. Error bars represent mean ± SEM of the replicate measurements (*p < 0.05, **p < 0.01, one-way
ANOVA for G6PD activity measurement and two-tailed unpaired Student’s t-test for NADPH measurement). Veh: vehicle, KO: knockout, CQ: chloroquine
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NaCl). Bovine thrombin (100 units) was added to the resin, which was followed by
overnight incubation at 4 °C with gentle shaking. Tag-less G6PD was eluted and
applied onto HiLoad 16/600 Superdex 75 pg size exclusion chromatography.
Fractions containing G6PD were pooled and concentrated using 10 kDa MWCO
membrane. The ﬁnal concentration of G6PD was determined by Bradford method,
and the protein was stored in 40% glycerol at −80 °C.
Enzyme assay and kinetic measurements. Enzyme activity was measured by
monitoring NADPH production, which was coupled with diaphorase converting
resazurin to ﬂuorescent resoruﬁn (excitation at 565 nm and emission at 590 nm)
(Supplementary Fig. 3a); ﬂuorescent signal was thus proportional to G6PD activity.
All the assays were performed at 25 °C and run for 5 min in buffer containing
50 mM Tris (pH 7.4), 0.5 mM EDTA, 3.3 mM MgCl2, 1 UmL−1 diaphorase and
0.1 mM resazurin. 10 ng of recombinant enzymes or 10 μg of cell lysates was used
for the assay with 10 μM NADP+ (Sigma) as cofactor and 100 μM G6P (Sigma) as
substrate. Steady-state kinetic parameters were obtained by varying concentrations
of NADP+ (0–10 μM) with a constant concentration of G6P (100 μM) and simi-
larly for G6P (0–100 μM) with a constant concentration of NADP+ (10 μM) with
10 ng of recombinant enzymes. Data analysis was performed using GraphPad
Prism software v.6 (GraphPad Software, La Jolla, CA USA). Kinetic parameters
were obtained by ﬁtting the data to the Michaelis–Menten equation.
High-throughput screening assay. The diaphorase-coupled enzyme assay as
described above was used to screen for small-molecule activators. All the com-
pounds purchased from SPECS, Chembridge, ChemDiv Kinase, LOPAC, Micro-
source Spectrum, Biomol FDA, Biomol ICCB, and NIH Clinical Collection were
added to Canton G6PD enzyme reaction mixture at a ﬁnal concentration of 16.67
μM using Caliper Life Sciences Staccato system with a Twister II robot and a
Sciclone ALH3000 (Caliper Life Sciences, Alameda, CA USA) integrated with a
V&P Scientiﬁc pin tool, which was followed by the incubation for 3 h. Then
addition of G6P initiated the reaction, which was run for 2.5 min. The ﬂuorescent
signals were recorded 4 times during the run using Molecular Devices AnalystGT
(Molecular Devices, Sunnyvale, CA USA). Any compounds showing 30% activa-
tion of the enzyme were rescreened in a dose-dependent manner (0–30 μM,
duplicate) to identify potential hits. The screening and data analysis were carried
out by Stanford University High-Throughput Bioscience Centers (HTBC).
Thermostability assay. 10 ng of recombinant enzymes was incubated at various
temperatures ranging from 25 to 65 °C for 20 min, and the activity was measured as
a
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Fig. 5 AG1 reduces hemolysis upon exposure to oxidative stressors. a AG1 reduced the extent of hemolysis of 5% erythrocyte suspension treated with
either 1 mM chloroquine (CQ) for 4 h under light or 1 mM diamide for 4 h at 37 °C (n= 7 independent blood samples, *p= 0.0372, **p= 0.0019, ****p <
0.0001, one-way ANOVA). b–d AG1 signiﬁcantly increased GSH levels and reduced ROS levels, when 5% erythrocyte suspension was exposed to either 1
mM chloroquine or diamide for 3 h at 37 °C, which was consistent with increased G6PD activity (n= 9–11, *p < 0.05, **p < 0.01, ****p < 0.0001, one-way
ANOVA). e Band 3 protein was clustered (cBand3) when 5% erythrocyte suspension was treated with chloroquine, which was alleviated by AG1
treatment. Each lane represents one individual sample, and quantiﬁcation is provided in Supplementary Fig. 7a. f–h AG1 (1 μM) improved storage of
erythrocytes (5% suspension) at refrigerated temperature by reducing hemolysis and concomitant protein leakage for 28 days (n= 13 independent blood
samples, *p < 0.05, two-tailed unpaired Student’s t-test), which corresponded with increased G6PD activity (n= 4, *p= 0.0323, ***p= 0.0003, one-way
ANOVA). Each sample was re-treated with AG1 every week. Representative hemolysis phenotypic images are provided below f. Error bars represent
mean ± SD. NT: no treatment, CQ: chloroquine, cBand3: clustered band 3 protein
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described above. After normalization of the data between 0 and 100, Boltzmann
sigmoidal equation was used to calculate the T1/2 value, the temperature at which
the enzyme retains half of original activity.
In vitro proteolysis assay. 200 ng of recombinant enzymes was incubated with
10 ng of chymotrypsin for 1 h at room temperature. 100 μM of the compound was
added to some reaction conditions. The following protein level was examined by
Western blot (original blot data are available in the Supplementary Information).
Overexpression of WT G6PD and Canton variant in SH-SY5Y cells. Prior to
the cellular-based assays using SH-SH5Y cells, the duration of overexpression of
WT G6PD and Canton variant was examined by transfecting the cells seeded in a
12-well plate. The genes encoding human WT G6PD and Canton variant were ﬁrst
PCR-ampliﬁed, which was then inserted into pcDNA 3.1/myc-His C (Thermo-
Fisher Scientiﬁc) using HindIII and XhoI restriction enzyme sites. 0.5 μg of cDNA
and 1.5 μg of lipofectamine (Invitrogen) were diluted in 50 μL of Opti-MEM
medium, respectively and incubated for 5 min. The diluted DNA was combined
with diluted lipofectamine, which was followed by incubation for 20 min prior to
the addition to cells. The transfected cells were collected at different time points (up
to 72 h), and the overexpressed G6PD levels were examined by Western blot. The
transfection was carried out in 50% serum-starved cells. Once the duration of
expression was conﬁrmed, other cellular-based assays were performed.
Cycloheximide chase assay. 50,000 cells (SH-SH5Y cells or ﬁbroblast cells) or
100,000 cells (lymphocytes) were seeded in a 12-well plate and incubated overnight.
The cells were subjected to serum starvation (50–75%) for 48 h and treated with
50 μg mL−1 of cycloheximide at different time points (0–48 h). The cells were
treated with the compound (1 μM) for 48 h together with cycloheximide. Then the
cells were collected in PBS containing protease inhibitor cocktail and 1% Triton
X-100 and centrifuged at 18,800 × g at 4 °C for 10 min. 10 μg of total protein was
loaded onto SDS–PAGE gels, and the protein levels were examined by Western blot
(original blot data are available in Supplementary Information).
Glutathione (GSH) measurement. Total glutathione level was measured using a
Total Glutathione Quantiﬁcation Kit (Dojindo), according to the manufacturer’s
instructions. Cells were subjected to serum starvation (50–75%) for 48 h to induce
oxidative stress and treated with the compound for 24 h before measurement. The
absorbance was read at 412 nm.
Cell viability assay. Cell viability was measured using a Cell-Counting Kit-8
(CCK-8, Dojindo), utilizing WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophe-
nyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt, according to the
manufacturer’s instructions. Cells were subjected to serum starvation (50–75%) for
48 h before measurement. Cells in 100 μL of medium per well were treated with
10 μL of CCK-8 solution and incubated for 2 h at 37 °C. The absorbance was read
at 450 nm. Viability of lymphocytes was measured by staining with a 0.4% solution
of trypan blue in buffered isotonic salt solution (pH 7.2). The viability was cal-
culated as the number of viable cells (non-stained by the dye) divided by the total
number of cells within the grids on the hemacytometer. Cells were treated with 1
μM of the compound 24 h before the measurement.
Cellular reactive oxygen species (ROS) measurement. Cells in a 96-well plate
were incubated with chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate (CM-
H2DCFDA) at a ﬁnal concentration of 5 μM in HBSS (Hank’s balanced salt
solution) for 30 min at 37 °C. After wash, cells were treated with Hoechst 33342
(Molecular Probes) to stain nuclei and incubated for another 10 min at 37 °C. Cells
were washed in HBSS, and the ﬂorescence was analyzed with excitation/emission at
485/525 nm. Cells were subjected to serum starvation (50–75%) for 48 h to induce
oxidative stress and treated with the compound for 24 h before measurement. The
signal was normalized to nuclei staining (excitation/emission at 350/470 nm).
Native gel electrophoresis. 200–300 ng of recombinant enzymes was incubated
with the compound (varying in assays) for 10min at room temperature. To prevent
streaking and artifacts in native PAGE gel, the samples in a native state (no boiling
of sample and no reducing agent in sample buffer) were electrophoresed by
SDS–PAGE. Cross-linking assay was initiated by incubating 200 ng of recombinant
enzymes in PBS with 0.1% of glutaraldehyde and different concentrations of
NADP+ (0, 10, 100, 1000 μM) or MgCl2 (0, 1, 10, 100mM). The mixture was
incubated for 10min at room temperature, which was followed by the addition of
100mM Tris (pH 8.0) at a ﬁnal concentration to terminate the reaction. The
samples were electrophoresed as described above.
G6PD siRNA-knockdown assay. Endogenous G6PD was knocked down in each
cell line as follows; 2 pmol of siRNA G6PD (Santa Cruz Biotechnology, sc-60667)
and 0.5 μg lipofectamine (Invitrogen) were diluted in 10 μL of Opti-MEM medium,
respectively and incubated for 5 min. The diluted siRNA was combined with
diluted lipofectamine, which was followed by additional incubation for 20 min
prior to the addition to cells in a 96-well plate.
Crystallization, data collection, structure determination and reﬁnement.
Crystals of WT G6PD recombinant enzyme grew in sitting drops containing 20%
w/v PEG 3350, 0.2 M potassium formate, pH 7.3. Suramin (G6PD inhibitor) was
added to the protein solution (the ﬁnal concentration in the drop was 0.5 mM)
prior to the crystallization. Canton G6PD recombinant enzyme was crystallized in
sitting drops containing 20% w/v PEG 3350, 0.2 M ammonium citrate tribasic, pH
7.0. AG1 dissolved in 30% DMSO was added to the protein prior to the crystal-
lization to reach ﬁnal concentration of 0.5 mM in the drop. None of the Suramin or
AG1 compound was visible in the electron density map of WT G6PD and Canton
G6PD; however, they signiﬁcantly improved diffracting quality of the crystals. Note
that our inability to observe AG1 in the crystal structure may reﬂect instability or
ﬂexibility of the ligand bound to G6PD. Additional crystallographic studies and
further medicinal chemistry efforts will help determine the binding site of AG1 in
the enzyme and the mechanism by which it activates G6PD. X-ray diffraction data
of WT G6PD and Canton G6PD were collected at 100 K at beamline 12–2 of
Stanford Synchrotron Radiation Light Source (SSRL) and beamline 5.0.2 of
Advanced Light Source (ALS), respectively. A solution of 20% glycerol was used as
cryo-protectant. Crystals of WT and Canton G6PD diffracted to 1.9 Å and 2.6 Å
resolution, respectively. The data were processed using iMOSFLM57, and further
analysis of the data by POINTLESS58,59 indicated the space group of F222 and
P212121 for WT G6PD and Canton G6PD crystals, respectively. WT G6PD
structure was solved using molecular replacement with a monomeric G6PD
structure from PDB: 2BHL used as a search model in MOLREP. Canton G6PD
structure was solved using the WT G6PD structure that was already solved in this
study. Molecular models were further built in Coot60. Both structures were reﬁned
using the restrained isotropic reﬁnement in REFMAC61,62. TLS parameters were
not used for the reﬁnement in both cases. Each reﬁnement was done using 10
cycles of maximum likelihood restrained reﬁnement, with geometry weight
adjusted to 0.05. Data collection and reﬁnement statistics are summarized in
Table 1. The atomic coordinates and structure factors are deposited in the PDB
database under accession codes PDB: 6E08 for WT G6PD and PDB: 6E07 for
Canton G6PD. All structure ﬁgures were prepared using PyMOL (PyMOL Mole-
cular Graphics System, Version 1.5.0.5; Schrödinger).
Zebraﬁsh husbandry. Adult zebraﬁsh (AB strain; 3–18 months old) were raised
according to standard protocols, and embryos were obtained through natural
mating and staged63. Adult tbx16b104/+ was a generous gift from S. Amacher (Ohio
State University). All animal procedures were performed according to NIH
guidelines and approved by the Committee on Administrative Panel on Laboratory
Animal Care (APLAC) at Stanford University. Embryos were raised in E3 medium
at 28.5 °C.
Zebraﬁsh crispants. sgRNA against exon 10 of g6pd was designed using
CHOPCHOP and in vitro transcribed using the T7 quick high yield RNA synthesis
kit (New England Biolabs, E2050S)64,65. The gene-speciﬁc oligo sequence was: 5′-T
AATACGACTCACTATAGAGAAGGGGAGGCAAAACTGGTTTTAGAGCTAG
AAATAGCAAG-3’. sgRNA and Cas9 protein (New England Biolabs, M0386T)
were mixed and microinjected into one-cell-stage embryos. For each injected
clutch, 10 individual embryos were isolated at 24 hpf for sequencing to conﬁrm
introduction of a CRISPR-mediated indel in exon 10.
Zebraﬁsh compound treatment. Embryos were dechorinated with pronase at
24 hpf and treated with 100 μg mL−1 of chloroquine and/or AG1 (1 μM) by directly
adding the compounds to the well. For ROS measurements, the embryos were
incubated with compounds for 5 h and then the ROS-detecting reagent (CM-
H2DCFDA) was added at a ﬁnal concentration of 500 ng mL−1 to the well and
incubated for 3 h. One embryo was placed to each well of a black, opaque 96-well
plate. The ﬂorescence was analyzed with excitation/emission at 485/525 nm. After
ROS assays, embryos at about 32 hpf were pooled and lysed in buffer containing
50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.1% NP-40 and protease
inhibitor cocktail, which was followed by three cycles of freeze and thawing in
liquid nitrogen. The lysate was centrifuged at 18,800 × g at 4 °C for 15 min. Total
protein concentration in the supernatants (total lysate) was determined by the
Bradford method. 10 μg of total lysate was used for enzymatic assay. 50 μg of total
lysate was used to measure NADPH levels using a NADPH quantiﬁcation kit
(Biovision), according to the manufacturer’s instructions. 50 μg of total lysate was
loaded onto 10% SDS–PAGE gels, and the protein levels were examined by
Western blot using anti-G6PD antibody (Abcam (G6PD: AB87230)).
Zebraﬁsh imaging. Live embryos were anesthetized and mounted in 3% methyl-
cellulose. Embryos were imaged with a Leica M205FA microscope equipped with a
1.0x Plan Apochromatic objective and a SPOT Flex camera or a Leica DM4500B
compound microscope equipped with a QImaging Retiga-SRV camera. For hemo-
globin staining, live embryos were stained in 0.6mgmL−1 o-dianisidine solution
containing 10mM sodium acetate (pH 4.5), 0.65% H2O2 and 40% ethanol in the dark
for 15min and cleared in glycerol37. Embryos were then mounted in 100% glycerol
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and imaged with a Leica M205FA microscope equipped with a 1.0x Plan Apochro-
matic objective and a SPOT Flex camera. All images were captured using SPOT or
MetaMorph imaging software (Diagnostic Imaging Inc.) and processed in Photoshop
(Adobe). Adjustments were limited to brightness levels and cropping. Analysis was
carried out by an observer blinded to the experimental conditions.
Blood sample assay. De-identiﬁed blood samples were obtained from the Stanford
Blood Center. Erythrocytes were collected by ﬁltering the samples through a cel-
lulose slurry to remove platelets and leukocytes and then washed with saline. G6PD
activity was measured spectrophotometrically by the Beutler method66. The activity
of all the samples used in this study was in a normal range (5–9 U g−1 Hb), sug-
gesting that the subjects have WT G6PD. 5% erythrocyte suspension was pre-
incubated with 1–5 μΜ AG1 at 4 °C overnight, which was followed by treatment
with (or without) either 1 mΜ chloroquine (CQ) or 1 mM diamide for 3–4 h at
37 °C (for hemolysis assay with chloroquine, the mixture was incubated under
light). Then centrifugation at 100 × g for 5 min was followed. Hemoglobin release
in the supernatant was monitored by measuring absorbance at 540 nm. Saline was
used as a negative control (0% hemolysis) and a sample treated with 0.1% Triton X-
100 was used as a positive control (100% hemolysis). For ROS measurement,
erythrocyte mixture was washed with saline by centrifugation after treatment and
incubated with chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate (CM-
H2DCFDA) at a ﬁnal concentration of 5 μM in saline at 37 °C for 15 min. After
wash, the samples were lysed with 0.1% Triton X-100 (ﬁnal concentration), and the
ﬂorescence was analyzed with excitation/emission at 485/525 nm. GSH measure-
ment was determined using a Cayman glutathione assay kit (Cayman Chemicals,
703002). Brieﬂy, 50 μL of diluted erythrocyte lysate samples were mixed with
150 μL of assay reagents including glutathione reductase, 5′,5-dithiobis-(2-nitro-
benzoic acid) (DTNB) and NADPH, which was followed by incubation for 25 min
at room temperature. The absorbance was read at 412 nm. For storage assay,
5% erythrocyte suspension was stored at 4 °C with and without 1 μM AG1, and
hemolysis and G6PD activity were monitored every week for 28 days to examine
whether AG1 improves preservation of erythrocytes over time. Protein leakage was
also examined by measuring the absorbance of the supernatant of samples at
280 nm. The samples were re-treated with AG1 every week.
Statistical analyses. Most assays were repeated at least in three independent
experiments. The data from in vitro and cell-based assays are presented as mean ±
standard error of the mean (SEM), and the data from the human erythrocyte study
are presented as mean ± standard deviation (SD). Statistical differences were cal-
culated by either Student’s t-test (two-tailed, unpaired), one-way ANOVA, or two-
way ANOVA using GraphPad Prism software. In assays with human erythrocytes,
each sample was utilized as its own control, and assay parameters were compared
before and after treatment; thus, randomization was not needed. For all zebraﬁsh
experiments, at least two breeding tanks, each containing 3–4 males and 3–5
females from separate stocks, were set up to generate embryos. Embryos from each
tank were randomly distributed across tested conditions. Unfertilized and devel-
opmentally abnormal embryos were removed prior to compound treatment. No
statistical methods were used to determine sample size per condition. For phe-
notypic analysis, raw counts for each condition were used for chi-square analysis or
Fisher’s exact test based on expected values. For all phenotypic analysis, the scorer
was blinded to treatment conditions. For ROS assays, the normality of each dis-
tribution was assessed using the Shapiro–Wilk test and determined to be non-
normal. A Kruskal–Wallis test with a Dunn’s secondary test was used to determine
differences between all conditions. p values were corrected for multiple compar-
isons testing. p values and number of samples or experiments replicated are
indicated within the ﬁgure legends, and p < 0.05 was considered statistically
signiﬁcant.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
author upon request. Protein structures have been deposited in the Protein Data Bank
(PDB) with accession codes of 6E07 and 6E08 for Canton G6PD and WT G6PD,
respectively.
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